GlassScriptPhysician profile
Walter Mitta
NPI 1932134731
$10,743.60
in general payments reported to CMS, 2019-2025
21 companies · $630 in 2025
The $630 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,262 · 2020: $1,686 · 2021: $2,066 · 2022: $1,995 · 2023: $1,114 · 2024: $990 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,953.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,951.49 | 2020-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,930.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,455.82 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $1,154.85 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $668.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $470.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.57 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $234.01 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $124.99 | 2019 | |
| Silk Road Medical, INC. | $101.92 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Novartis Pharmaceuticals Corporation | $85.23 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $58.31 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $53.69 | 2020 | |
| Pfizer INC. | $32.47 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $22.55 | 2023 | Inpefa |
| Xeris Pharmaceuticals, INC. | $19.99 | 2021 | |
| Astellas Pharma US INC | $16.10 | 2020 | |
| Evoke Pharma, INC. | $15.33 | 2020 | |
| Eisai INC. | $12.76 | 2021 | |
| Esperion Therapeutics, INC. | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Mitta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.